bactroban ointment 2% ww
glaxosmithkline pte ltd - mupirocin - ointment - 2% w/w - mupirocin 2% w/w
engerix-b vaccine 10 mcg0.5 ml
glaxosmithkline pte ltd - hepatitis b surface antigen protein (yeast) - injection - 10 mcg/0.5 ml - hepatitis b surface antigen protein (yeast) 10 mcg/0.5 ml
flolan for infusion 0.5 mgvial
glaxosmithkline pte ltd - epoprostenol - injection, powder, for solution - 0.5 mg/vial - epoprostenol 0.5 mg/vial
fortum for injection 1 gvial
glaxosmithkline pte ltd - ceftazidime pentahydrate eqv ceftazidime - injection, powder, for solution - 1 g/vial - ceftazidime pentahydrate eqv ceftazidime 1 g/vial
rotarix oral suspension (tube)
glaxosmithkline pte ltd - human rotavirus, live, attenuated, rix 4414 strain - suspension - not less than 10⁶ ccid₅₀/dose (1.5 ml) - human rotavirus, live, attenuated, rix 4414 strain not less than 10⁶ ccid₅₀/dose (1.5 ml)
synflorix suspension for injection (prefilled syringe)
glaxosmithkline pte ltd - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d; diphtheria toxoid (dt) carrier protein; polysaccharide (ps); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae); tetanus toxoid (tt) carrier protein - injection, suspension - 1 μg ps1; 1.11-1.67 μg pd/dose - conjugate of streptococcus pneumoniae type 1 & haemophilus influenzae protein d 1 μg ps1; 1.11-1.67 μg pd/dose; conjugate of streptococcus pneumoniae type 14 and haemophilus influenzae protein d 1 μg ps14; 1.00-1.82 μg pd/dose; conjugate of streptococcus pneumoniae type 18c and tetanus toxoid 3 μg ps18c; 5.45-10.00 μg tt/dose; conjugate of streptococcus pneumoniae type 19f and diphtheria toxoid 3 μg ps19f; 3.33-6.00 μg dt/dose; conjugate of streptococcus pneumoniae type 23f and haemophilus influenzae protein d 1 μg ps23f; 0.39-0.74 μg pd/dose; conjugate of streptococcus pneumoniae type 4 and haemophilus influenzae protein d 3 μg ps4; 3.33-6.67 μg pd/dose; conjugate of streptococcus pneumoniae type 5 and haemophilus influenzae protein d 1 μg ps5; 0.67-1.25 μg pd/dose; conjugate of streptococcus pneumoniae type 6b and haemophilus influenzae protein d 1 μg ps6b; 0.56-0.95 μg pd/dose; conjugate of streptococcus pneumoniae type 7f and haemophilus influenzae protein d 1 μg ps7f; 0.87-1.43 μg pd/dose; conjugate of streptococcus pneumoniae type 9v and haemophilus influenzae protein d 1 μg ps9v; 1.00-1.82 μg pd/dose; diphtheria toxoid (dt) carrier protein 3-6 μg dt/dose (total dt content); polysaccharide (ps) 16 μg/dose (total ps content); protein-d (pd) carrier protein (derived from non-typeable haemophilus influenzae) 9-16 μg pd/dose (total pd content); tetanus toxoid (tt) carrier protein 5-10 μg/dose (total tt content)
niquitin 2mg medicated chewing gum
glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 20mg - drugs used in nicotine dependence - it is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt. permanent cessation of tobacco use is the eventual objective
niquitin 4mg medictated chewing gum
glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 4mg - drugs used in nicotine dependence - e treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt
niquitin fresh mint 2mg medicated chewing gum
glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 2mg - drugs used in nicotine dependence - it m is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attempt
niquitin fresh mint 4mg medicated chewing gum
glaxosmithkline consumer healthcare (ireland) limited - nicotine - medicated chewing gum - 4mg - drugs used in nicotine dependence - it is used for the treatment of tobacco dependence by relief of nicotine withdrawal symptoms including cravings during a quit attemp